Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 14, 2018

SELL
$17.39 - $31.12 $347,800 - $622,400
-20,000 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$15.16 - $25.75 $303,200 - $515,000
20,000
20,000 $497,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $998M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Morgens Waterfall Vintiadis & CO Inc Portfolio

Follow Morgens Waterfall Vintiadis & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgens Waterfall Vintiadis & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Morgens Waterfall Vintiadis & CO Inc with notifications on news.